Compounds > phosphorylethanolamine
Page last updated: 2024-10-20

phosphorylethanolamine and Neoplasms

phosphorylethanolamine has been researched along with Neoplasms in 17 studies

phosphorylethanolamine: RN given refers to parent cpd; structure
O-phosphoethanolamine : The ethanolamine mono-ester of phosphoric acid, and a metabolite of phospholipid metabolism. This phosphomonoester shows strong structural similarity to the inhibitory neurotransmitter GABA, and is decreased in post-mortem Alzheimer's disease brain.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"Pimasertib showed a favourable pharmacokinetic profile with high absolute bioavailability and a unique metabolic pathway (conjugation with phosphoethanolamine)."2.82Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients. ( Johne, A; Massimini, G; Scheible, H; Udvaros, I; von Richter, O, 2016)

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19901 (5.88)18.7374
1990's2 (11.76)18.2507
2000's3 (17.65)29.6817
2010's11 (64.71)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ledford, H1
Escobar, H1
Luna, AC1
Saraiva, GK1
Filho, OM1
Chierice, GO1
Neto, SC1
Cuccovia, IM1
Maria, DA1
Alves, SM1
Delduque, MC1
Santos, AO1
von Richter, O1
Massimini, G1
Scheible, H2
Udvaros, I1
Johne, A2
Paumgartten, FJ1
Pavlov, VA1
Kotomtsev, VV1
Doronin, AI1
Sabadash, EV1
Kraetzer, F1
Marx, A1
Wimmer, E1
Gallego-Ortega, D1
Ramirez de Molina, A1
Ramos, MA1
Valdes-Mora, F1
Barderas, MG1
Sarmentero-Estrada, J1
Lacal, JC1
Zhu, L1
Kate, P1
Torchilin, VP1
SMITH, LC1
ROSSI, FM1
Arias-Mendoza, F1
Zakian, K1
Schwartz, A1
Howe, FA1
Koutcher, JA1
Leach, MO1
Griffiths, JR1
Heerschap, A1
Glickson, JD1
Nelson, SJ1
Evelhoch, JL1
Charles, HC1
Brown, TR1
Mintz, A1
Wang, L1
Ponde, DE1
Podo, F1
Redmond, OM1
Bell, E1
Stack, JP1
Dervan, PA1
Carney, DN1
Hurson, B1
Ennis, JT1
Al-Kattan, A1
Girod-Fullana, S1
Charvillat, C1
Ternet-Fontebasso, H1
Dufour, P1
Dexpert-Ghys, J1
Santran, V1
Bordère, J1
Pipy, B1
Bernad, J1
Drouet, C1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I, Open-Label, Single Center Trial to Investigate the Mass Balance, Metabolite Profile and Oral Bioavailability of Pimasertib in Cancer Patients With Locally Advanced or Metastatic Solid Tumors[NCT01713036]Phase 16 participants (Actual)Interventional2012-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Apparent Terminal Elimination Rate Constant (λz) of Total [14C] Radioactivity

λz of total [14C] radioactivity was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression on terminal data points of the curve. (NCT01713036)
Timeframe: Pre dose, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 48.0, 72.0, 96.0 and 168.0 hours post [14C]-labeled pimasertib dose on Day 8

Interventionper hour (Geometric Mean)
Pimasertib0.04084

Apparent Terminal Half-life (t1/2) of Total [14C] Radioactivity

(NCT01713036)
Timeframe: Pre dose, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 48.0, 72.0, 96.0 and 168.0 hours post [14C]-labeled pimasertib dose on Day 8

Interventionhour (Median)
Pimasertib14.41

Apparent Volume of Distribution of Total [14C] Radioactivity During the Terminal Phase Following Oral Administration (Vz/f)

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Vz/f of total radioactivity during the terminal phase was calculated by dividing the dose with the product of area under the plasma concentration time curve and apparent terminal rate constant (dose/AUC0inf*λz). (NCT01713036)
Timeframe: Pre dose, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 48.0, 72.0, 96.0 and 168.0 hours post [14C]-labeled pimasertib dose on Day 8

InterventionLiter (Geometric Mean)
Pimasertib253.5

Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of [14C]-Pimasertib Following IV Administration on Day 1

(NCT01713036)
Timeframe: Pre-dose, 0.5, 1, 1.5, 3, 5, 7, 9, 11, 15, 23, and 47 hours post [14C] intravenous pimasertib dose on Day 1

Interventionhour*picogram equivalent/milliliter (Geometric Mean)
Pimasertib37.4

Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Pimasertib Following Oral Administration on Day 1

(NCT01713036)
Timeframe: Pre-dose, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 8, 10, 12, 16, 24, and 48 hours post unlabeled pimasertib dose on Day 1

Interventionhour*nanogram/milliliter (Geometric Mean)
Pimasertib957.4

Area Under the Plasma Concentration Time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Total [14C] Radioactivity

Area under the plasma concentration time curve from time zero to the last sampling time at which the concentration is at or above the lower limit of quantification was calculated by using mixed log linear trapezoidal rule. Unit of assessment was hour*nanogram equivalent per milliliter (hr*ng eq/mL). (NCT01713036)
Timeframe: Pre dose, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 48.0, 72.0, 96.0 and 168.0 hours post [14C]-labeled pimasertib dose on Day 8

Interventionhr*ng eq/mL (Geometric Mean)
Pimasertib5318

Area Under the Plasma Concentration Time Curve From Time Zero to the Last Sampling Time Point (AUC0-t) of [14C]-Pimasertib Following Intravenous (IV) Administration on Day 1

(NCT01713036)
Timeframe: Pre-dose, 0.5, 1, 1.5, 3, 5, 7, 9, 11, 15, 23, and 47 hours post [14C] intravenous pimasertib dose on Day 1

Interventionhour*picogram equivalent/milliliter (Geometric Mean)
Pimasertib36.0

Area Under the Plasma Concentration Time Curve From Time Zero to the Last Sampling Time Point (AUC0-t) of Pimasertib Following Oral Administration on Day 1

(NCT01713036)
Timeframe: Pre-dose, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 8, 10, 12, 16, 24, and 48 hours post unlabeled pimasertib dose on Day 1

Interventionhour*nanogram/milliliter (Geometric Mean)
Pimasertib937.2

Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Total [14C] Radioactivity

Area under the concentration time curve (AUC) from time zero to infinity (AUC0-inf) was calculated from AUC0-t + AUCextra, where AUCextra = Clast calc/λz. Clast calc was the calculated plasma concentration at the last sampling time point at which plasma concentration was at or above the lower limit of quantification was measured and λz represents apparent terminal elimination rate constant. (NCT01713036)
Timeframe: Pre dose, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 48.0, 72.0, 96.0 and 168.0 hours post [14C]-labeled pimasertib dose on Day 8

Interventionhr*ng eq/mL (Geometric Mean)
Pimasertib5711

Blood/ Plasma Concentration Ratios of Total [14C] Radioactivity

(NCT01713036)
Timeframe: 1.5 hour post [14C]-labeled pimasertib dose on Day 8

InterventionRatio (Mean)
Pimasertib0.687

Fraction Unbound of [14C] Pimasertib

Fraction of unbound drug (fu) is defined as the ratio of unbound drug concentration to the total drug concentration multiplied by 100. (NCT01713036)
Timeframe: 1.5 hour post [14C]-labeled pimasertib dose on Day 8

Interventionpercentage of unbound drug (Mean)
Pimasertib6.702

Maximum Observed Plasma Concentration (Cmax) of Intravenous [14C] Pimasertib

(NCT01713036)
Timeframe: Pre-dose, 0.5, 1, 1.5, 3, 5, 7, 9, 11, 15, 23, and 47 hours post [14C] intravenous pimasertib dose on Day 1

Interventionpicogram equivalent per milliliter (Geometric Mean)
Pimasertib12.67

Maximum Observed Plasma Concentration (Cmax) of Total [14C] Radioactivity

Unit of assessment was nanogram equivalent per milliliter (ng eq/mL). (NCT01713036)
Timeframe: Pre dose, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 48.0, 72.0, 96.0 and 168.0 hours post [14C]-labeled pimasertib dose on Day 8

Interventionng eq/mL (Geometric Mean)
Pimasertib774.1

Maximum Observed Plasma Concentration (Cmax) of Unlabeled Pimasertib

(NCT01713036)
Timeframe: Pre-dose 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 8, 10, 12, 16, 24, and 48 hours post unlabeled pimasertib dose on Day 1

Interventionng/mL (Geometric Mean)
Pimasertib265

Oral Bioavailability of Pimasertib After Single Oral Dose of Unlabeled Pimasertib and Intravenous (IV) Single Tracer Dose of [14C] Pimasertib

Oral bioavailability (F) was calculated using the formula=AUC0-inf oral/dose oral) / (AUC0-inf iv/dose iv) * 100%, where AUC0-inf is the area under the concentration time curve (AUC) from time zero to infinity. (NCT01713036)
Timeframe: Pre-dose, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 8, 10, 12, 16, 24, and 48 hours post unlabeled pimasertib dose on Day 1; Pre-dose, 0.5, 1, 1.5, 3, 5, 7, 9, 11, 15, 23, and 47 hours post [14C] labeled pimasertib dose on Day 1

Interventionpercentage bioavailability (Number)
Pimasertib73

The Volume of Distribution of the Central or Plasma Compartment (Vc) of Intravenous [14C] Pimasertib

The volume of distribution of the central or plasma compartment (Vc) was calculated using the formula=Dose/C0 (NCT01713036)
Timeframe: Pre-dose, 0.5, 1, 1.5, 3, 5, 7, 9, 11, 15, 23, and 47 hours post intravenous [14C] pimasertib dose on Day 1

InterventionLiter (Geometric Mean)
Pimasertib83.668

Time to Reach Maximum Plasma Concentration (Tmax) of Total [14C] Radioactivity

(NCT01713036)
Timeframe: Pre dose, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 48.0, 72.0, 96.0 and 168.0 hours post [14C]-labeled pimasertib dose on Day 8

Interventionhour (Median)
Pimasertib1.5

Total Body Clearance of Total [14C] Radioactivity From Plasma Following Oral Administration (CL/f)

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/f was influenced by the fraction absorbed. Apparent body clearance of total radioactivity from plasma was calculated by dividing the dose with area under the plasma concentration time curve from zero to infinity (Dose/AUC0inf). (NCT01713036)
Timeframe: Pre dose, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 48.0, 72.0, 96.0 and 168.0 hours post [14C]-labeled pimasertib dose on Day 8

Interventionliter per hour (Geometric Mean)
Pimasertib10.35

Apparent Terminal Elimination Rate Constant (λz) of M445 and M554

The λz of M445 and M554 was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression on terminal data points of the curve. (NCT01713036)
Timeframe: Predose, 1.0, 2.0, 4.0, 10 and 24 hour post [14C]-labeled pimasertib dose on Day 8

Interventionper hour (Geometric Mean)
M445M554
Pimasertib0.25420.07021

Apparent Terminal Elimination Rate Constant (λz) of Unlabeled Pimasertib and Intravenous [14C] Pimasertib

Apparent terminal elimination rate constant (λz) was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression on terminal data points of the curve. (NCT01713036)
Timeframe: Pre-dose, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 8, 10, 12, 16, 24, and 48 hours post unlabeled pimasertib dose on Day 1; Pre-dose, 0.5, 1, 1.5, 3, 5, 7, 9, 11, 15, 23, and 47 hours post intravenous [14C] labeled pimasertib dose on Day 1

Interventionper hour (Geometric Mean)
Unlabeled pimasertibIntravenous [14C] pimasertib
Pimasertib0.10960.1994

Apparent Terminal Half-life (t1/2) of M445 and M554

(NCT01713036)
Timeframe: Predose, 1.0, 2.0, 4.0, 10 and 24 hour post [14C]-labeled pimasertib dose on Day 8

Interventionhour (Median)
M445M554
Pimasertib2.65310.81

Apparent Volume of Distribution During the Terminal Phase Following Oral Administration (Vz/f) and the Apparent Volume of Distribution During the Terminal Phase Following Intravenous Administration (Vz) of [14C] Pimasertib

The apparent volume of distribution during the terminal phase following oral administration (Vz/f) and the apparent volume of distribution during the terminal phase following intravenous administration was calculated by using the formula=Dose/( AUC0-inf* λz). (NCT01713036)
Timeframe: Pre-dose, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 8, 10, 12, 16, 24, and 48 hours post unlabeled pimasertib dose on Day 1; Pre-dose, 0.5, 1, 1.5, 3, 5, 7, 9, 11, 15, 23, and 47 hours post [14C] labeled pimasertib dose on Day 1

InterventionLiter (Geometric Mean)
Unlabeled pimasertibIntravenous [14C] pimasertib
Pimasertib571.77229.35

Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of M445 and M554

AUC from time 0 to infinity (AUC0-inf), was calculated from AUC0-t + AUCextra, where AUCextra = Clast calc/lambda z (λz). Clast calc was the calculated plasma concentration at the last sampling time point at which plasma concentration was at or above the lower limit of quantification was measured and λz represents apparent terminal elimination rate constant. (NCT01713036)
Timeframe: Predose, 1.0, 2.0, 4.0, 10 and 24 hour post [14C]-labeled pimasertib dose on Day 8

Interventionhr*ng eq/mL (Geometric Mean)
M445M554
Pimasertib1134.723135.61

Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time (AUC0-t) of M445 and M554

Area under the plasma concentration-time curve from time zero to the last sampling time (AUC0-t) at which the concentration is at or above the lower limit of quantification. (NCT01713036)
Timeframe: Predose, 1.0, 2.0, 4.0, 10 and 24 hour post [14C]-labeled pimasertib dose on Day 8

Interventionhr*ng eq/mL (Geometric Mean)
M445M554
Pimasertib976.391410.30

Mass Balance: Amount of Total Radioactivity Recovered Into the Urine and Feces From Time Zero to the Last Sampling Time Point (Ae0-t)

Recovery of total [14C]-radioactivity was determined in excreta, i.e., urine and feces at each sampling period subsequent to oral administration of [14C]-pimasertib on Day 8. Cumulative recovery of total [14C]-radioactivity in terms of percentage of dose recovered in urine and feces and total percentage of dose recovered was reported for the outcome measure. (NCT01713036)
Timeframe: Urine: 0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours post [14C]-labeled pimasertib dose on Day 8; Feces: 0-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours post [14C]-labeled pimasertib dose on Day 8

Interventionpercentage of dose recovered (Geometric Mean)
UrineFecesTotal
Pimasertib52.830.785.1

Maximum Observed Plasma Concentration (Cmax) of M445 and M554

Maximum observed plasma concentration (Cmax) for the metabolites M445 and M554 was calculated. (NCT01713036)
Timeframe: Predose, 1.0, 2.0, 4.0, 10 and 24 hour post [14C]-labeled pimasertib dose on Day 8

InterventionNanogram equivalent per milliliter (Geometric Mean)
M445M554
Pimasertib300.93174.64

Number of Metabolites Identified Overall and as Major

Identification and profiling of the metabolites was done. The total number of metabolites and the number of metabolites identified as major were reported. (NCT01713036)
Timeframe: Pre-dose 1.0, 2.0, 4.0, 10 and 24 hours post [14C]-labeled Pimasertib dose on Day 8

Interventionmetabolites (Number)
OverallMajor
Pimasertib142

Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death, and TEAEs Leading to Discontinuation

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug administration until 30+/-2 days after the last dose of study drug administration that were absent before treatment or that worsened relative to pre treatment state. (NCT01713036)
Timeframe: Part A and B: From the first dose of study drug administration until 30+/-2 days after the last dose of study drug administration, assessed up to 18 months

Interventionsubjects (Number)
TEAEsSerious TEAEsTEAEs leading to deathTEAEs leading to discontinuation
Pimasertib6213

Part B: Number of Subjects Who Experienced Complete Response (CR), Partial Response (PR), Stable Disease (SD) and Progressive Disease (PD)

Anti tumor activity defined as CR, PR, or stable disease and PD based on the investigator tumor evaluations performed every 2 cycles in accordance with Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. CR =Disappearance of all target lesions except lymph nodes (LN); LN must have a decrease in the short axis to less than (<)10 millimeter (mm); PR = 30% decrease in sum of diameters of target lesions taking as reference the baseline sum diameters; Progressed Disease (PD) = 20% increase in sum of diameters of target lesions; the appearance of >=1 new lesions; SD= Neither shrinkage to qualify for PR nor increase to qualify for PD taking the smallest sum diameters on study as reference. For non-target lesions a CR = Disappearance of all non-target lesions and all LN must be non-pathological in size <10 mm; Non-CR/Non PD: persistence of one or more non-target lesions; PD = unequivocal progression of existing non-target lesions or appearance of new ones. (NCT01713036)
Timeframe: From the screening every 2 cycles until end of the treatment, assessed up to 18 months

Interventionsubjects (Number)
Stable diseaseProgressive diseaseConfirmed ResponsePartial ResponseNon evaluable
Pimasertib31001

Plasma Concentrations of [14C] Pimasertib

(NCT01713036)
Timeframe: Pre-dose 1.0, 2.0, 4.0, 10 and 24 hours post [14C]-labeled Pimasertib dose on Day 8

Interventionnanogram equivalent per milliliter (Mean)
PredoseHour 1Hour 2.0Hour 4.0Hour 10.0Hour 24.0
Pimasertib0.0695.2691.2379.3165.646.62

Plasma Concentrations of Pimasertib Metabolites

Plasma concentration of the Pimasertib metabolite M445 and M554 were presented for the outcome measure. (NCT01713036)
Timeframe: Predose, 1.0, 2.0, 4.0, 10 and 24 hour post [14C]-labeled pimasertib dose on Day 8

InterventionNanogram equivalent per milliliter (Mean)
M445 (Predose)(n=6)M445 (Hour 1.0)(n=6)M445 (Hour 2.0)(n=6)M445 (Hour 4.0)(n=6)M445 (Hour 10.0)(n=5)M445 (Hour 24.0)(n=3)M554(Predose)(n=6)M554(Hour 1.0)(n=6)M554 (Hour 2.0)(n=6)M554 (Hour 4.0)(n=6)M554 (Hour 10.0) (n=5)M554 (Hour 24.0) (n=3)
Pimasertib0.0285.2262.285.0528.580.00.087.53167.6169.1108.851.33

Time to Reach Maximum Plasma Concentration (Tmax) of M445 and M554

Time to reach maximum plasma concentration (Tmax) for the metabolites M445 and M554 was calculated. (NCT01713036)
Timeframe: Predose, 1.0, 2.0, 4.0, 10 and 24 hour post [14C]-labeled pimasertib dose on Day 8

Interventionhour (Median)
M445M554
Pimasertib1.54

Time to Reach Maximum Plasma Concentration (Tmax) of Unlabeled Pimasertib and Intravenous [14C] Pimasertib

(NCT01713036)
Timeframe: Pre-dose 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 8, 10, 12, 16, 24, and 48 hours post unlabeled pimasertib dose on Day 1; Pre-dose, 0.5, 1, 1.5, 3, 5, 7, 9, 11, 15, 23, and 47 hours post intravenous [14C] labeled pimasertib dose on Day 1

Interventionhours (Median)
Unlabeled pimasertib[14C] intravenous pimasertib
Pimasertib0.750.5

Total Body Clearance of Unlabeled Pimasertib (CL/f) and Intravenous [14C] Pimasertib (CL)

The total body clearance of drug from plasma following oral administration (Cl/f) and the total body clearance of drug from plasma following intravenous administration was calculated by dividing the Dose with area under the plasma concentration time curve from time zero to infinity (AUC0 inf)=Dose/AUC0- inf. (NCT01713036)
Timeframe: Pre-dose, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 8, 10, 12, 16, 24, and 48 hours post unlabeled pimasertib dose on Day 1; Pre-dose, 0.5, 1, 1.5, 3, 5, 7, 9, 11, 15, 23, and 47 hours post intravenous [14C] labeled pimasertib dose on Day 1

Interventionliter per hour (Geometric Mean)
Unlabeled pimasertibIntravenous [14C] pimasertib
Pimasertib62.6745.73

Reviews

2 reviews available for phosphorylethanolamine and Neoplasms

ArticleYear
Methodological standardization for a multi-institutional in vivo trial of localized 31P MR spectroscopy in human cancer research. In vitro and normal volunteer studies.
    NMR in biomedicine, 2004, Volume: 17, Issue:6

    Topics: Biomarkers, Tumor; Ethanolamines; Humans; Internationality; Magnetic Resonance Spectroscopy; Multice

2004
Tumour phospholipid metabolism.
    NMR in biomedicine, 1999, Volume: 12, Issue:7

    Topics: Animals; Ethanolamines; Humans; Magnetic Resonance Spectroscopy; Neoplasms; Phosphatidylcholines; Ph

1999

Trials

3 trials available for phosphorylethanolamine and Neoplasms

ArticleYear
Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.
    British journal of clinical pharmacology, 2016, Volume: 82, Issue:6

    Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Carbon Radioisotopes; Ethanola

2016
Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors.
    Drug metabolism and disposition: the biological fate of chemicals, 2017, Volume: 45, Issue:2

    Topics: Adolescent; Adult; Aged; Biotransformation; Ethanolamines; Humans; Male; MAP Kinase Kinase 1; MAP Ki

2017
Methodological standardization for a multi-institutional in vivo trial of localized 31P MR spectroscopy in human cancer research. In vitro and normal volunteer studies.
    NMR in biomedicine, 2004, Volume: 17, Issue:6

    Topics: Biomarkers, Tumor; Ethanolamines; Humans; Internationality; Magnetic Resonance Spectroscopy; Multice

2004

Other Studies

13 other studies available for phosphorylethanolamine and Neoplasms

ArticleYear
Drugs on demand.
    Nature, 2015, Nov-26, Volume: 527, Issue:7579

    Topics: Animals; Brazil; Clinical Trials as Topic; Compassionate Use Trials; Drug Industry; Ethanolamines; H

2015
Brazilian courts tussle over unproven cancer treatment.
    Nature, 2015, Nov-26, Volume: 527, Issue:7579

    Topics: Animals; Brazil; Compassionate Use Trials; Ethanolamines; Humans; Mice; Neoplasms; Patient Advocacy;

2015
CANCER RESEARCH. Brazil bill would legalize renegade cancer pill.
    Science (New York, N.Y.), 2016, Apr-01, Volume: 352, Issue:6281

    Topics: Antineoplastic Agents; Brazil; Clinical Trials as Topic; Dosage Forms; Drug Approval; Ethanolamines;

2016
Potential antitumor activity of novel DODAC/PHO-S liposomes.
    International journal of nanomedicine, 2016, Volume: 11

    Topics: Antineoplastic Agents; Cell Cycle; Cell Proliferation; Cells, Cultured; Ethanolamines; Human Umbilic

2016
Law 13,269/2016: clamor by society trumps the scientific method!
    Cadernos de saude publica, 2016, Jun-20, Volume: 32, Issue:6

    Topics: Antineoplastic Agents; Brazil; Clinical Trials as Topic; Drug Approval; Ethanolamines; Health Policy

2016
Phosphoethanolamine: anticancer pill bandwagon effectThe authors replyLei nº 13.269/2016: a comoção da sociedade vence o método científico!Câncer: esperança e ciência.
    Cadernos de saude publica, 2016, Oct-20, Volume: 32, Issue:10

    Topics: Brazil; Drugs, Investigational; Ethanolamines; Humans; Legislation, Drug; Neoplasms

2016
Antioxidant and Antimutagenic Metabolites in Animals with Opposite Sensitivity to Tuberculosis Mycobacteria and Mutagenic Xenobiotics.
    Bulletin of experimental biology and medicine, 2016, Volume: 162, Issue:1

    Topics: Animals; Disease Susceptibility; Ethanolamine; Ethanolamines; Glutathione; Guinea Pigs; Liver; Methi

2016
Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment.
    PloS one, 2009, Nov-12, Volume: 4, Issue:11

    Topics: Alternative Splicing; Animals; Cell Line, Tumor; Cell Membrane; Choline Kinase; Dogs; Ethanolamines;

2009
Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting.
    ACS nano, 2012, Apr-24, Volume: 6, Issue:4

    Topics: Animals; Cell Line, Tumor; Ethanolamines; Liposomes; Matrix Metalloproteinase 2; Mice; Nanostructure

2012
Quantitative determination of ethanolamine phosphate and free amino acids of normal and neoplastic tissue.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1954, Volume: 87, Issue:3

    Topics: Amino Acids; Amino Alcohols; Ethanolamines; Neoplasms

1954
Comparison of radiolabeled choline and ethanolamine as probe for cancer detection.
    Cancer biology & therapy, 2008, Volume: 7, Issue:5

    Topics: Carbon Radioisotopes; Cell Line, Tumor; Choline; Ethanolamine; Ethanolamines; Fibroblasts; Fluorine

2008
Tissue characterization and assessment of preoperative chemotherapeutic response in musculoskeletal tumors by in vivo 31P magnetic resonance spectroscopy.
    Magnetic resonance in medicine, 1992, Volume: 27, Issue:2

    Topics: Adult; Aged; Bone Neoplasms; Chemotherapy, Adjuvant; Ethanolamines; Female; Glycerylphosphorylcholin

1992
Biomimetic nanocrystalline apatites: Emerging perspectives in cancer diagnosis and treatment.
    International journal of pharmaceutics, 2012, Feb-14, Volume: 423, Issue:1

    Topics: Apatites; Biological Availability; Biomimetic Materials; Calcium Compounds; Cell Line, Tumor; Cell S

2012